|45.57||+0.8100||+1.81%||Vol 803.79K||1Y Perf 45.34%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||67.09||Analyst Rating||Strong Buy 1.22|
|Potential %||47.22||Finscreener Ranking||★★★★ 53.61|
|Insiders Trans % 3/6/12 mo.||-100/-100/-94||Value Ranking||★ 42.31|
|Insiders Value % 3/6/12 mo.||-100/-100/-93||Growth Ranking||★★ 45.33|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-91||Income Ranking||— -|
|Market Cap||3.66B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||60.89||Earnings Date||5th May 2021|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-1.69|
|EPS Growth Next 5 Years %||42.30|
|Avg. Weekly Volume||685.62K|
|Avg. Monthly Volume||724.65K|
|Avg. Quarterly Volume||646.72K|
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) stock closed at 45.57 per share at the end of the most recent trading day (a 1.81% change compared to the prior day closing price) with a volume of 808.63K shares and market capitalization of 3.66B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 374 people. Apellis Pharmaceuticals Inc. CEO is Cedric Francois.
The one-year performance of Apellis Pharmaceuticals Inc. stock is 45.34%, while year-to-date (YTD) performance is -20.33%. APLS stock has a five-year performance of %. Its 52-week range is between 25.49 and 58.47, which gives APLS stock a 52-week price range ratio of 60.89%
Apellis Pharmaceuticals Inc. currently has a PE ratio of -9.10, a price-to-book (PB) ratio of 16.33, a price-to-sale (PS) ratio of 13.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.82%, a ROC of -134.00% and a ROE of -285.23%. The company’s profit margin is -62.96%, its EBITDA margin is -79 204.40%, and its revenue ttm is $250.65 Million , which makes it $3.12 revenue per share.
Of the last four earnings reports from Apellis Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.69 for the next earnings report. Apellis Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Apellis Pharmaceuticals Inc. is Strong Buy (1.22), with a target price of $67.09, which is +47.22% compared to the current price. The earnings rating for Apellis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apellis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apellis Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.89, ATR14 : 2.66, CCI20 : 201.11, Chaikin Money Flow : -0.15, MACD : -0.76, Money Flow Index : 66.69, ROC : 8.37, RSI : 63.57, STOCH (14,3) : 68.20, STOCH RSI : 1.00, UO : 52.17, Williams %R : -31.80), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apellis Pharmaceuticals Inc. in the last 12-months were: A. Sinclair Dunlop (Sold 50 000 shares of value $2 631 567 ), Alec Machiels (Option Excercise at a value of $86 775), Alec Machiels (Sold 32 500 shares of value $1 244 700 ), Cedric Francois (Option Excercise at a value of $437 877), Cedric Francois (Sold 40 000 shares of value $1 396 050 ), David Watson (Option Excercise at a value of $432 646), David Watson (Sold 17 433 shares of value $885 473 ), Federico Grossi (Option Excercise at a value of $130 440), Federico Grossi (Sold 21 212 shares of value $894 713 ), Lukas Scheibler (Option Excercise at a value of $199 994), Nicole Perry (Option Excercise at a value of $90 240), Nicole Perry (Sold 24 000 shares of value $1 214 480 ), Pascal Deschatelets (Option Excercise at a value of $16 688), Pascal Deschatelets (Sold 6 250 shares of value $317 125 ), Paul Fonteyne (Buy at a value of $318 068), Victoria L. Brown (Option Excercise at a value of $227 760), Victoria L. Brown (Sold 12 000 shares of value $420 000 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.